Share：
Share this content in WeChat
X
[Chinese][PDF]753116
• Review •
Research progress of magnetic resonance imaging in Parkinson disease
WANG Bo  DAI Min-fang 

DOI:10.3969/j.issn.1674-8034.2013.06.013.


[Abstract] Excessive iron accumulation in the brain has been suggested to be a kind of potent toxin, which can initiate and propagate the production of free radicals. leading to lipid peroxidation in Parkinson disease. MR, especially with the use of T2 or T2* sequences including susceptibility weighted imaging (SWI), is an effective method to detect and measure brain iron. The effect of MR on detecting brain iron and abnormal deposition of iron in the brain with PD was reviewed in this article.
[Keywords] Parkinson disease；Iron；Brain；Magnetic resonance imaging

WANG Bo * Department of Magnetic Resonance Imaging, the First People’s Hospital of Yunnan Province, Kunming 650032, China

DAI Min-fang Department of Magnetic Resonance Imaging, the First People’s Hospital of Yunnan Province, Kunming 650032, China

*Correspondence to: Wang B, E-mail: wangbo871@sina.com

Conflicts of interest   None.

Received  2013-10-08
Accepted  2013-10-25
DOI: 10.3969/j.issn.1674-8034.2013.06.013
DOI:10.3969/j.issn.1674-8034.2013.06.013.

[1]
Almeida OP, Burton EJ, Mckeith I, et al. MRI study of caudate nucleus volume in Parkinson’s disease with and without dementia wlth lewy bodies and Alzheimer’s disease. Dement Geriatr Cogn Disord, 2003, 16(2): 57-63.
[2]
张静，张云亭，何宁，等．磁敏感加权成像对帕金森病患者丘脑底核的显示价值初探．磁共振成像, 2011, 2(5): 353-357.
[3]
Caslake R, Moore JN, Gordon JC, et al. Changes in diagnosis with follow-up in an incident cohort of patients with psrkinsonism. J Neurol Neurosurg Psychiatry, 2008, 78(11): 1202-1207.
[4]
Hodaie M, Neimat JS, Lozano AM. The dopaminergic nigrostriatal system and Parkinson’s disease: molecular strategies. Neurosurgery, 2007, 60(1): 17-28.
[5]
Sohmiya M, Tanaka M, Aihara Y, et al. Structural changes in the midbrain with aging and Parkinson’s disease: an MRI study. Neurobiol Aging, 2004, 25(4):449-453.
[6]
Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology, 2008(70): 1411-1417.
[7]
Atasoy HT, Nuyan O, Tunc T, et al. T2-weighted MRI in Parkinson disease：substantia nigra pars compacta hypointensity correlates with the clinical scores. Neurol India, 2004, 52(3): 332-337.
[8]
陶静，周滟，戈欣，等. SWI序列在早期原发性帕金森病中的应用价值．医学影像学杂志, 2009, 19(9): 1073-1077.
[9]
Wallis LI, Paley MN, Graham JM, et al. MRI assessment of basal ganglia iron deposition in Parkinson’s disease. Magn Reson Imaging, 2008, 28(5): 1061-1067.
[10]
黄新明，孙斌，薛蕴菁，等．磁敏感加权成像在测量帕金森病黑质铁沉积面积中的初步应用．中华神经医学杂志, 2011, 10(9): 922-924.
[11]
Geng DY, Li YX, Zee OS. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson’s disease. Neurosurgery, 2006, 58(2): 256-262.
[12]
Michaeli S, Oz G, Sorce DJ, et al. Assessment of brain iron and neuronal integrity in patients with Parkinson’s disease using novel MRI contrasts. Mov Disord, 2007, 22(3): 334-338.
[13]
Song R, Song HK. Echo-spacing optimization for the simultaneous measurement of reversible(R2’) and irreversible(R2) transverse relaxation rates. Magn Reson Imaging, 2007, 25(1): 63-68.
[14]
Jensen JH, Chandra R, Ramani A, et al. Magnetic field correlation imaging. Magn Reson Med, 2006, 55(6): 1350-1361.
[15]
Vertinsky AT, Coenen VA, Lang DJ, et al. Localization of the subthalamicnucleus: optimization withsusceptibility-weighted phase MR imaging. AJNR Am J Neuroradiol, 2009, 30(9): 1717-1724.
[16]
Manova ES, Habib CA, Boikov AS, et al. Characterizing theme-sencephalon using susceptibilityweighted imaging. AJNR Am JNeuroradiol, 2009, 30(3): 569-574.
[17]
Haller S, Badoud S, Nguyen D, et al. Differentiation between Parkinson disease and other forms of Parkinsonism using support vector machine analysis of susceptibility-weighted imaging (SWI). initial results. Eur Radiol, 2013, 23(1):12-19.
[18]
Paraskevi K, Maria IA, Sofia M, et al. MRI evaluation of the basal ganglia size and iron content in patients with Parkinson’s disease. J Neurol, 2006, 253(1): 26-32.
[19]
Szumowski J, Bas E, Gaarder K, et al. Measurement of brain iron distribution in Hallevorden-Spatz syndrome. J Magn Reson Imaging, 2010, 31(2): 482-489.
[20]
王玉红，沈钧康，刘春风，等．帕金森病患者脑灰质核团T2弛豫时间的初步研究．医学影像学杂志, 2010, 20(1): 9-13.
[21]
Haacke EM, Ayaz M, Khan A. Establishing a baseline phase behavior in magnetic resonance imaging to determine normal and abnormal iron content in the brain. Magn Reson Imaging, 2007, 26(2): 256-264.
[22]
王慈，范国光，徐克，等．磁敏感加权成像定量测量在鉴别诊断帕金森病和血管性帕金森氏综合症中的应用．中国医学影像学杂志, 2012, 20(3): 161-165.
[23]
Zhang J, Zhang Y, Wang J. Characterizing iron deposition in Parkinson' s disease using suceptibility-weighted imaging: an in vivo MR study. Brain Res, 2010(3): 124-130.
[24]
Han YH, Lee JH, Kang BM, et al. Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system. J Neurol Sci, 2013, 325(1): 29-35.
[25]
Wang Y, Butros SR, Shuai X, et al. Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. AJNR Am J Neuroradiol, 2012, 33(2)2: 266-273.
[26]
Haacke EM, Mittal S, Wu Z, et al. Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. AJNR Am JNeuroradiol, 2009, 30(1): 19-30.
[27]
王波，马莎，戴敏方，等．原发性单侧症状帕金森病SWI脑铁沉积的定量研究．中国临床医学影像杂志, 2013, 24(4): 234-238.
[28]
Boelmans K, Holst B, Hackius M, et al.Brain iron deposition fingerprints in Parkinson’s disease and progressive supranuclear palsy. Mov Disord, 2012, 27(3): 421-427.
[29]
卢琦，黄建军，张兰慧，等．磁共振波谱分析在帕金森病早期诊断中的应用研究．中国CT和MRI杂志, 2009, 7(5): 1-4.
[30]
吴武林，王小宜，娄明武，等．小脑半球1H-MRS在帕金森病和帕金森叠加综合征中的应用．实用放射学杂志, 2012, 28(10): 1506-1509.
[31]
Grger A, Chadzynski G, Godau J, et al. Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease. Eur Radiol, 2011, 21(9): 1962-1969.
[32]
Lucetti C, Del Dotto P, Gambaccini G, et al. Influences of dopaminergic treatment on motor cortex in Parkinson disease: a M RI/MRS study. Mov Disord, 2007, 22(15): 2170-2175.
[33]
Henehcliffe C, Shungu DC, Mao X, et al. Multinuclear magnetic resonance spectroscopy for in vivo assessment of mitochondrial dysfunction in Parkinson's disease. Ann N Y Acad Sci, 2008, 1147(2): 206-220.
[34]
Hattingen E, Magerkurth J, Pilatus U, et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson’s disease. Brain, 2009, 132(Pt 12): 3285-3297.
[35]
Yoshikawa K, Nakata Y, Yamada K, et al. Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. J Neurol Neurosurg Psychiatry, 2004, 75(3): 481-484.
[36]
李飞平，沈加林，许建荣，等．弥散张量成像对早期帕金森病的研究价值．中国医学计算机成像杂志, 2010, 16(4): 273-276.
[37]
Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology, 2009, 72(16): 1378-1384.
[38]
Gattellaro G, Minati L, Grisoli M, et al. W hite matter involvement in idiopathic Parkinson disease: a diffusion tensor imaging study. Am J Neuroradiol, 2009, 30(6): 1222-1226.
[39]
Scherfler C, Schocke MF, Seppi K, et al. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson’s disease. Brain, 2006, 129(pt 2)：538-542.
[40]
李建，范国光，徐克，等．扩散张量成像观察早期帕金森病患小脑.中国医学影像技术, 2011, 27(7): 1361-1365.

PREV Cardiovascular magnetic resonance imaging: Part III——The clinical applications of cardiovascular magnetic resonance
NEXT The research status and advance of functional MRI in amblyopia
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn